Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 14/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24704163 | 1.00 | TBXAS1 (0.54) | TBXAS1CYP19A1CYP11B2PDE4APDE4B | |
| SCHEMBL126574 | 1.00 | TBXAS1 (0.54) | TBXAS1CYP19A1CYP11B2PDE4APDE4B | |
| SCHEMBL24704165 | 0.95 | POLB (0.53) | TBXAS1CYP19A1CYP11B2PDE4APDE4B | |
| SCHEMBL24704167 | 0.84 | PDE4A (0.56) | TBXAS1CYP19A1CYP11B2PDE4APDE4B | |
| SCHEMBL127735 | 0.84 | PDE4A (0.56) | TBXAS1CYP19A1CYP11B2PDE4APDE4B | |
| SCHEMBL127734 | 0.84 | PDE4A (0.56) | TBXAS1CYP19A1CYP11B2PDE4APDE4B | |
| Benzene SCHEMBL28266121 | 0.83 | PDE4A (0.67) | CYP19A1CYP11B2PDE4APDE4BPDE4C | |
| SCHEMBL247446 | 0.83 | PDE4A (0.67) | CYP19A1CYP11B2PDE4APDE4BPDE4C | |
| SCHEMBL15131514 | 0.82 | POLB (0.51) | TBXAS1CYP19A1CYP11B2POLBALDH1A1 | |
| SCHEMBL27481022 | 0.81 | POLB (0.50) | TBXAS1CYP19A1CYP11B2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022255228-A1 | COMPOSITION, CURED PRODUCT OR COMPACT, OPTICAL MEMBER, AND LENS | 富士フイルム株式会社 | 2022-12-08 | — | — | WO | disclosed |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| EP-1874765-B1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE AND USES THEREOF | GALAPAGOS SAS (FR) | 2012-03-07 | — | — | EP | disclosed |
| EP-2354137-A1 | Urea derivatives, methods for their manufacture, and uses thereof | Galapagos SAS (FR) | 2011-08-10 | — | — | EP | disclosed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | disclosed |
| EP-1874765-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | Proskelia SAS (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117211-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | PROSKELIA SAS (FR) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | UTS2R, UGP2, SLC14A1 | TBXAS1 1105/4885CYP19A1 1089/4885CYP11B2 399/4885 |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | UGP2, UTS2R, UMPS | TBXAS1 1663/4885CYP19A1 2279/4885CYP11B2 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.